$Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma$

Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma

Lenalidomide is an oral immunomodulatory drug that has helped improve outcomes in multiple myeloma (MM) patients. Combination lenalidomide and dexamethasone (Len+Dex) has been shown to increase response rates and prolong survival compared with dexamethasone alone in patients with relapsed or refract...

Full description

Bibliographic Details
Main Authors:	Alegre, Adrian, Vicuña, Isabel, Aguado, Beatriz
Format:	Online
Language:	English
Published:	Libertas Academica 2011
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256976/

Similar Items

Lenalidomide for the treatment of relapsed and refractory multiple myeloma
by: van de Donk, Niels WCJ, et al.
Published: (2012)

Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma
by: Chen, Christine, et al.
Published: (2009)

Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma
by: Siegel, D S, et al.
Published: (2014)

Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma
by: Siegel, D S, et al.
Published: (2014)

Use of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in Korea
by: Kim, Hyo Jung, et al.
Published: (2015)

Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma
by: Dimopoulos, M A, et al.
Published: (2014)

Efficacy of dose-reduced lenalidomide in patients with refractory or recurrent multiple myeloma
by: Schwamborn, Katharina, et al.
Published: (2011)

Immortal time bias in retrospective analysis: comment on ‘Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma'
by: Hsieh, P-Y, et al.
Published: (2015)

Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus
by: Cortés-Hernández, Josefina, et al.
Published: (2012)

Pharmacokinetics and safety of ixazomib plus lenalidomide–dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study
by: Gupta, Neeraj, et al.
Published: (2015)

Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma
by: Dimopoulos, M A, et al.
Published: (2011)

Lenalidomide in Combination with Dexamethasone in Elderly Patients with Advanced, Relapsed or Refractory Multiple Myeloma and Renal Failure
by: Tosi, Patrizia, et al.
Published: (2013)

Pembrolizumab (MK-3475) in combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-023
by: Mateos, Maria-Victoria, et al.
Published: (2015)

Gastrointestinal relapse of multiple myeloma and sustained response to lenalidomide: a case report
by: Benusiglio, Patrick R, et al.
Published: (2011)

Bendamustine in patients with relapsed or refractory multiple myeloma
by: Michael, M, et al.
Published: (2010)

Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma
by: Yang, Wen-Chi, et al.
Published: (2015)

Efficacy and Safety of Panobinostat in Relapsed or/and Refractory Multiple Myeloma: Meta Analyses of Clinical Trials and Systematic Review
by: Liu, Jing-di, et al.
Published: (2016)

A phase II study of lenalidomide in patients with relapsed or refractory ATLL
by: Phillips, Adrienne A, et al.
Published: (2014)

Lenalidomide in the Treatment of Lymphoproliferative Disorders and Multiple Myeloma
by: Liberati, Anna Marina, et al.
Published: (2013)

Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study
by: Jian Hou, et al.
Published: (2017-07-01)

High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide
by: Pourabdollah, Maryam, et al.
Published: (2016)

Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program
by: Du, Xin, et al.
Published: (2016)

Efficacy and Safety of Lenalidomide in the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis of Randomized Controlled Trials
by: Qiao, Shu-Kai, et al.
Published: (2015)

Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma
by: Jain, Salvia, et al.
Published: (2011)

Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib
by: Nooka, Ajay, et al.
Published: (2013)

Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma
by: Fostier, Karel, et al.
Published: (2012)

Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma
by: Terpos, Evangelos, et al.
Published: (2013)

Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma
by: Cerchione, Claudio, et al.
Published: (2016)

Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib
by: Kumar, S K, et al.
Published: (2015)

Clinical Outcome of Bortezomib Retreatment in Patients with Relapsed or Refractory Multiple Myeloma
by: Ahn, Jae-Sook, et al.
Published: (2014)

Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib
by: Atrash, S, et al.
Published: (2015)

Single Agent Lenalidomide Activity in Multiple Myeloma Relapse Evidenced Uniquely by CT/PET
by: Gozzetti, Alessandro, et al.
Published: (2012)

Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study
by: Joseph Mikhael, et al.
Published: (2018-08-01)

Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma
by: Baertsch, Marc-Andrea, et al.
Published: (2016)

Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison
by: Prince, H Miles, et al.
Published: (2007)

Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study
by: Offidani, M, et al.
Published: (2013)

A Review of the Efficacy of Thalidomide and Lenalidomide in the Treatment of Refractory Prurigo Nodularis
by: Lim, Victoria M., et al.
Published: (2016)

Lenalidomide before and after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
by: Tuchman, S. A., et al.
Published: (2012)

Biological Activity of Lenalidomide and Its Underlying Therapeutic Effects in Multiple Myeloma
by: Martiniani, Roberta, et al.
Published: (2012)

Paradoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myeloma
by: Maïga, S, et al.
Published: (2013)